Drug Trial Radar · NCT01387711
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology
Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Aug 2011
Primary completion
Jun 2012
Study completion Jun 2012
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 4, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will be conducted to explore the biological effects in the skin following treatment with PEP005 Gel, 0.05% administered for two consecutive days, assessed by histology.
Conditions
- Actinic Keratosis
Interventions
PEP005 (Ingenol mebutat Gel, 0.05 %)Drug
All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area
Primary outcomes
What the sponsor says the trial is designed to measure.
- Leukocytes Infiltration and degree of necrosis of the AK lesion and skinTime frame: From baseline until day 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Universitätsmedizin Göttingen, Georg-August-Universität
Göttingen, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.